Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine

被引:0
|
作者
John Strang
Rebecca McDonald
Gabrielle Campbell
Louisa Degenhardt
Suzanne Nielsen
Alison Ritter
Ola Dale
机构
[1] Institute of Psychiatry,King’s College London, National Addiction Centre
[2] Psychology and Neuroscience,National Drug and Alcohol Research Centre
[3] South London and Maudsley NHS Foundation Trust,Monash Addiction Research Centre
[4] University of New South Wales,Department of Circulation and Medical Imaging
[5] Monash University,St. Olav’s Hospital
[6] Norwegian University of Science and Technology,undefined
[7] University Hospital of Trondheim,undefined
来源
Drugs | 2019年 / 79卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Naloxone is a well-established essential medicine for the treatment of life-threatening heroin/opioid overdose in emergency medicine. Over two decades, the concept of ‘take-home naloxone’ has evolved, comprising pre-provision of an emergency supply to laypersons likely to witness an opioid overdose (e.g. peers and family members of people who use opioids as well as non-medical personnel), with the recommendation to administer the naloxone to the overdose victim as interim care while awaiting an ambulance. There is an urgent need for more widespread naloxone access considering the growing problem of opioid overdose deaths, accounting for more than 100,000 deaths worldwide annually. Rises in mortality are particularly sharp in North America, where the ongoing prescription opioid problem is now overlaid with a rapid growth in overdose deaths from heroin and illicit fentanyl. Using opioids alone is dangerous, and the mortality risk is clustered at certain times and contexts, including on prison release and discharge from hospital and residential care. The provision of take-home naloxone has required the introduction of new legislation and new naloxone products. These include pre-filled syringes and auto-injectors and, crucially, new concentrated nasal sprays (four formulations recently approved in different countries) with speed of onset comparable to intramuscular naloxone and relative bioavailability of approximately 40–50%. Choosing the right naloxone dose in the fentanyl era is a matter of ongoing debate, but the safety margin of the approved nasal sprays is superior to improvised nasal kits. New legislation in different countries permits over-the-counter sales or other prescription-free methods of provision. However, access remains uneven with take-home naloxone still not provided in many countries and communities, and with ongoing barriers contributing to implementation inertia. Take-home naloxone is an important component of the response to the global overdose problem, but greater commitment to implementation will be essential, alongside improved affordable products, if a greater impact is to be achieved.
引用
收藏
页码:1395 / 1418
页数:23
相关论文
共 50 条
  • [21] Take-home naloxone: a building block of drug emergency prophylaxis in Germany
    Fleissner, Simon
    Stoever, Heino
    Schaeffer, Dirk
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2023, : 1035 - 1041
  • [22] Take-Home Naloxone, Release From Jail, and Opioid Overdose-A Piece of the Puzzle
    Balter, Dylan Rose
    Howell, Benjamin A.
    JAMA NETWORK OPEN, 2024, 7 (12)
  • [23] Take-home naloxone kits preventing overdose deaths
    Eggertson, Laura
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2014, 186 (01) : 17 - 17
  • [25] Peer navigation and take-home naloxone for opioid overdose emergency department patients: Preliminary patient outcomes (vol 94, pg 29, 2018)
    Samuels, Elizabeth A.
    Bernstein, Steven L.
    Marshall, Brandon D. L.
    Krieger, Maxwell
    Baird, Janette
    Mello, Michael J.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2019, 99 : 8 - 8
  • [26] Take-home Naloxone for Trained Opioid Addicts - How Do They Deal with Overdose Emergencies
    von Essen, Heike Wodarz
    Wolstein, Jorg
    Pogarell, Oliver
    Wodarz, Norbert
    NOTARZT, 2022, 38 (03): : 138 - 142
  • [27] Take home naloxone in opioid overdose survivors
    Morales, Elena
    Willhite, Laurie
    Olives, Travis
    Weber, Lynn
    CLINICAL TOXICOLOGY, 2019, 57 (10) : 1017 - 1018
  • [28] Protocol for Take-home naloxone In Multicentre Emergency (TIME) settings: feasibility study
    Jones, Matthew
    Bell, Fiona
    Benger, Jonathan
    Black, Sarah
    Buykx, Penny
    Dixon, Simon
    Driscoll, Tim
    Evans, Bridie
    Edwards, Adrian
    Fuller, Gordon
    Goodacre, Steve
    Hoskins, Rebecca
    Hughes, Jane
    John, Ann
    Jones, Jenna
    Moore, Chris
    Sampson, Fiona
    Watkins, Alan
    Snooks, Helen
    PILOT AND FEASIBILITY STUDIES, 2020, 6 (01)
  • [29] Factors Associated With Participation in an Emergency Department Based Take-Home Naloxone Program for At-Risk Opioid Users
    Kestler, Andrew
    Buxton, Jane
    Meckling, Gray
    Giesler, Amanda
    Lee, Michelle
    Fuller, Kirsten
    Hong Quian
    Marks, Dalya
    Scheuermeyer, Frank
    ANNALS OF EMERGENCY MEDICINE, 2017, 69 (03) : 340 - 346
  • [30] Rates of Naloxone Prescriptions Following Implementation of a Take-Home Naloxone Program from the Emergency Department
    Lebin, J. A.
    Chen, B. C.
    Korab, G.
    Jablonowski, K.
    Whiteside, L. K.
    ANNALS OF EMERGENCY MEDICINE, 2017, 70 (04) : S101 - S101